UBS Maintains Buy on CRH, Lowers Price Target to $135
UBS analyst Julian Radlinger maintains CRH (NYSE:CRH) with a Buy and lowers the price target from $147 to $135.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Benzinga